(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of 38% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Gossamer Bio's revenue in 2026 is $48,471,000.On average, 11 Wall Street analysts forecast GOSS's revenue for 2026 to be $5,623,557,589, with the lowest GOSS revenue forecast at $0, and the highest GOSS revenue forecast at $11,582,261,467. On average, 11 Wall Street analysts forecast GOSS's revenue for 2027 to be $16,370,769,689, with the lowest GOSS revenue forecast at $4,554,046,637, and the highest GOSS revenue forecast at $30,064,593,596.
In 2028, GOSS is forecast to generate $30,505,822,604 in revenue, with the lowest revenue forecast at $5,015,459,525 and the highest revenue forecast at $87,292,934,755.